Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

FDA Approves AbbVie’s New Rheumatoid Arthritis Drug

Reuters Staff  |  August 19, 2019

(Reuters)—The U.S. Food and Drug Administration (FDA) on Friday approved AbbVie Inc.’s new treatment for rheumatoid arthritis (RA), a win for the drugmaker seeking to widen its portfolio as its blockbuster flagship therapy Humira (adalimumab)‎‎ faces competition.

The drug, Rinvoq (upadacitinib), is a JAK inhibitor.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

It is set to compete with Pfizer Inc.’s Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib).

Rinvoq’s label has a warning that flags risks of serious infections and lymphoma. In a notice, the FDA also said that patients taking JAK inhibitors in general risked developing blood clots.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

AbbVie has been aggressively fending off competition for Humira by signing deals with rival companies to prevent their cheap versions of the drug from entering the U.S., its biggest market, until 2023.

Humira, which treats RA and psoriasis, is the world’s best-selling medicine and brought in global revenue of $4.87 billion in the second quarter. But sales have been falling as it faces competition from cheaper rivals in Europe.

To further diversify its pipeline, in June, AbbVie announced a deal to buy Botox-maker Allergan Plc. for $63 billion.

It has also launched a new psoriasis medicine, Skyrizi (risankizumab-rzaa), to help retain some market share.

Shares of the company rose 2.2% to $64.36 in early afternoon trade.


Reference

  1. U.S. Food and Drug Administration. Drugs: Highlights and prescribing information: Rinvoq (upadacitinib). 2019 Aug.

Share: 

Filed under:Drug Updates Tagged with:AbbVieFDAFDA approvalRheumatoid Arthritis (RA)U.S. Food and Drug Administration (FDA)upadacitinib

Related Articles

    Health Canada Approves Upadacitinib to Treat Adults with PsA

    July 6, 2021

    Based on data from two phase 3 clinical trials, Health Canada has approved the use of upadacitinib to treat adults with active psoriatic arthritis.

    ajt/shutterstock.com

    FDA Approves Upadacitinib for Non-Radiographic Axial Spondyloarthritis

    October 27, 2022

    The FDA has approved upadacitinib for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) based on a short-term study that demonstrated improved pain, function and other symptoms of nr-axSpA in patients with active disease.

    Trial Pits Upadacitinib vs. Adalimumab for Psoriatic Arthritis

    October 14, 2021

    StudioMolekuul / shutterstock.com As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis fac­tor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medi­cine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg…

    FDA Approves Upadacitinib for RA

    September 2, 2019

    Results from multiple phase 3 clinical trails have led to the FDA approval of upadacitinib to treat patients with moderate to severe active RA…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences